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Abstract
Background: Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two
randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of
multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics.
Methods: Study 1: adults (18-65 years) with mild asthma received MEDI-528 (0.3, 1, 3 mg/kg) or placebo
subcutaneously twice weekly for 4 weeks. Study 2: adults (18-50 years) with stable, mild to moderate asthma and
exercise-induced bronchoconstriction received 50 mg MEDI-528 or placebo subcutaneously twice weekly for
4 weeks. Adverse events (AEs), pharmacokinetics (PK), immunogenicity, asthma control (including asthma
exacerbations), and exercise challenge test were evaluated in study 1, study 2, or both.
Results: In study 1 (N = 36), MEDI-528 showed linear serum PK; no anti-MEDI-528 antibodies were detected.
Asthma control: 1/27 MEDI-528-treated subjects had 1 asthma exacerbation, and 2/9 placebo-treated subjects had
a total of 4 asthma exacerbations (one considered a serious AE). In study 2, MEDI-528 (n = 7) elicited a trend in the
reduction in mean maximum decrease in FEV1 post-exercise compared to placebo (n = 2) (-6.49% MEDI-528 vs
-12.60% placebo; -1.40% vs -20.10%; -5.04% vs -15.20% at study days 28, 56, and 150, respectively). Study 2 was
halted prematurely due to a serious AE in an asymptomatic MEDI-528-treated subject who had an abnormal brain
magnetic resonance imaging that was found to be an artifact on further evaluation.
Conclusions: In these studies, MEDI-528 showed an acceptable safety profile and findings suggestive of clinical
activity that support continued study in subjects with mild to moderate asthma.
Trial registration: ClinicalTrials (NCT): NCT00507130 and ClinicalTrials (NCT): NCT00590720
Background
Asthma continues to be a significant health problem [1],
with nearly 8% of the US population reported to have
asthma in 2006 [2]. In one study, approximately 30% of
>3,400 asthmatics failed to achieve control despite regu-
lar use of combination therapy with high-dose inhaled
corticosteroids (ICS) and long-acting b2-agonists [3].
Interleukin (IL)-9, a 144 amino acid-long protein
secreted by CD4
+ T-helper 2 (Th2) cells, mast cells,
eosinophils, and neutrophils [4-7], may be associated
with airway hyperresponsiveness (AHR) and inflamma-
tion [8-11]. Evidence supporting IL-9 as a potential
target treatment for asthma emerged from a series of
genetic experiments linking AHR to a region on chro-
mosome 13 in mice, which contains the IL-9 gene
and is syntenic with the 5q31-q33 chromosome in
humans [8].
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has been shown to cause airway inflammation with pul-
monary infiltration of eosinophils and lymphocytes, air-
way obstruction, and mast cell hyperplasia [9,10,12]. In
contrast, anti−IL-9 antibody therapy has led to reduced
levels of AHR in murine models of allergen-induced
asthma [13,14].
Blocking IL-9 expression inhibits airway inflammation
in a mast cell-dependent murine model of asthma. Mast
cell-deficient animals demonstrated reduced lung inflam-
mation and AHR compared with wild-type control mice
[15]. An IL-9-neutralizing monoclonal antibody effec-
tively reduced lung recovery of mast cell precursors and
inflammatory cells after allergen challenge [16]. These
findings suggest that IL-9 promotes asthma pathology in
a mast cell-dependent manner through the proliferation
of mast cell precursors or the recruitment of immature
mast cells to lung tissue, or both.
Mast cell degranulation and release of spasmogenic
mediators have been reported to cause bronchoconstric-
tion in subjects with exercise-induced asthma [17,18].
Exercise challenge is an indirect airway challenge that
results in airway narrowing due to the release of media-
tors from mast cell degranulation, as opposed to direct
airway challenges such as methacholine that act directly
on the airway smooth muscle to produce bronchocon-
striction [19].
Additionally, in asthmatics, bronchial biopsy speci-
mens revealed increased IL-9 immunoreactive cells and
IL-9 mRNA, protein, and receptor levels compared with
those of healthy controls [20-23]. These data suggest
that IL-9-targeted therapies may offer a novel approach
for treating patients with asthma and may reduce
exercise-induced bronchoconstriction (EIB).
MEDI-528 is a humanized anti-IL-9 monoclonal anti-
body. Results from 2 open-label, phase 1 studies demon-
strated that MEDI-528, administered as a single
intravenous or subcutaneous (SC) dose, had an acceptable
safety profile in healthy volunteers, with no serious adverse
events (AEs) and a linear pharmacokinetic (PK) profile [24].
We report the results of 2 studies evaluating the
safety, tolerability, PK, and immunogenicity profiles of
multiple SC doses of MEDI-528, and the potential
reduction of EIB in subjects with mild to moderate
asthma. Study 2 was halted prematurely due to a serious
AE (SAE) in an asymptomatic MEDI-528-treated subject
who had an abnormal brain magnetic resonance imaging
( M R I )t h a tw a sf o u n dt ob ea na r t i f a c to nf u r t h e r
evaluation.
Methods
Subjects
Adults aged 18-65 years with mild persistent asthma
(forced expiratory volume in 1 second [FEV1]o rp e a k
expiratory flow [PEF] ≥80% of predicted) receiving ther-
apy with short-acting b2-agonists (SABA), inhaled corti-
costeroids (ICS) <264 μg/day fluticasone or equivalent,
or both (study 1) and adults aged 18-50 years with
stable mild to moderate persistent asthma receiving
therapy with SABA, ICS <800 μg / d a yb u d e s o n i d eo r
equivalent, and EIB (decrease in FEV1 of ≥15% from
baseline during screening) (study 2) were eligible [25].
Exclusion criteria included lung disease other than
asthma, use of systemic immunosuppressive drugs, and
smoking history ≥10 pack-years. Long-acting b2-agonists,
cromolyn sodium, nedocromil sodium, leukotriene recep-
tor antagonists, theophylline, and omalizumab were not
allowed (studies 1 and 2).
Study design
Study 1 was a randomized, double-blind, placebo-
controlled, dose-escalation, multicenter study evaluating
the safety, tolerability, PK, and immunogenicity profiles
of multiple SC doses of MEDI-528. For each cohort
(0.3 mg/kg, 1 mg/kg, or 3 mg/kg), subjects were rando-
m i z e d3 : 1v i aa ni n t e r a c t i v ev o i c er e s p o n s es y s t e m
(IVRS) to receive MEDI-528 or placebo as SC injections
twice weekly for 4 weeks through study day 24; there-
after, subjects were monitored for 126 days. Dosing at
each next higher dose group commenced after all evalu-
able subjects from the previous lower dose group com-
pleted evaluations on study day 56 with acceptable
safety profiles. Subjects who received ≥7 doses of the
study drug were considered evaluable. Those not evalu-
able were replaced, unless they withdrew from the study
due to safety reasons. The primary outcome for this
study was the safety and tolerability of multiple SC
doses of MEDI-528. Secondary outcomes included PK
and immunogenecity of MEDI-528 in this subject popu-
lation. Exploratory outcomes included effects of MEDI-
528 on pulmonary function, asthma exacerbations,
symptoms, rescue SABA use, and quality of life.
Study 2 was a randomized, double-blind, placebo-
controlled, multicenter study evaluating the safety and
tolerability profiles of multiple SC doses of MEDI-528
in three cohorts of 50, 100, and 200 mg versus placebo.
Subjects were randomized 2:1 via IVRS to receive
MEDI-528 or placebo as an SC injection twice weekly
for 4 weeks; thereafter, subjects were monitored for
126 days. Subjects who received ≥4 doses of study drug
(unless they discontinued for safety reasons) and had
≥2 exercise challenge tests (baseline and post-therapy)
were considered evaluable. The primary outcome of this
study was the safety and tolerability of multiple SC
doses of MEDI-528 in adult subjects with stable asthma
and EIB. Secondary objectives included the effect of
MEDI-528 on EIB and immunogenicity. Exploratory
outcomes included the effects of MEDI-528 on
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methacholine challenge testing, asthma exacerbations,
asthma symptoms, rescue SABA use, quality of life, and
nasal allergy symptoms in this population.
In both studies, all subjects and protocol-associated
personnel were blinded to the individual subject treat-
ment assignment until the last subject in each cohort
completed the study and the databases were locked.
Both studies were conducted in accordance with the
Declaration of Helsinki and were approved by an insti-
tutional review board/independent ethics committee at
each participating site. Written informed consent was
obtained from each subject before study entry.
Safety profile
In both studies, AEs and SAEs were monitored after the
first dose through day 150. AEs were graded by severity
(mild, moderate, severe) and relationship to study drug
(none, remote, possible, probable, definite) as deter-
mined by each investigator. Other safety measures
included routine laboratory tests, vital signs, electrocar-
diograms (ECGs), and physical examinations. Physical
examination included assessments for splenomegaly
(palpable spleen), lymphadenopathy, and neurologic
abnormalities.
In both studies, a noncontrast MRI of the brain was
performed at screening and day 28. MRI was added to
the current studies and other MEDI-528 studies [24]
based on preclinical toxicology findings of lymphohis-
tiocytic perivascular infiltrates in the brains of cyno-
molgus monkeys seen in both treated and control
animals. The study and peer-review pathologists con-
sidered this a spontaneous background finding unre-
lated to treatment. Subsequent MEDI-528 toxicology
studies in monkeys and of MM9C1 in mice found no
evidence of macroscopic or microscopic pathologic
changes in the brain; MRI is therefore not required for
subsequent clinical studies of MEDI-528 (data on file,
MedImmune, LLC).
Subjects in both studies who received any dose of
study drug were included in the safety analyses.
Pharmacokinetics and immunogenicity
In study 1, blood samples for measuring serum con-
centrations of MEDI-528 were collected before dosing
and at specified times throughout the study. As pre-
viously described [24], a validated enzyme-linked
immunosorbent assay (ELISA) was used for these mea-
surements. Unknown values with calculated concentra-
tions below the assay’s lower limit of quantitation
(< 1.25 μg/mL) were reported as less than the limit of
quantitation.
A double-antigen sandwich ELISA was performed to
evaluate anti-MEDI-528 antibodies [24].
Excercise challenge test
In study 2, exercise challenge was performed at baseline
prior to dosing and on study days 28, 56, and 150 after
dosing [26]. A response to therapy was defined as a
maximum decrease in post-exercise FEV1 of <10%,
b a s e do nA m e r i c a nT h o r a c i cS ociety guidelines [27].
Spirometry was performed 15 minutes before initiation
of the treadmill test and 5, 10, 15, 20, and 30 minutes
after the treadmill test was completed. At each time
point, maximum FEV1 was determined. The decrease in
FEV1 at each time point after the treadmill test was cal-
culated as a percentage of the best baseline FEV1.
Asthma control and quality of life
In both studies, an asthma exacerbation was defined as a
worsening of asthma requiring oral corticosteroids, a
doubling of the ICS dose from baseline, hospitalization,
emergency department visit, or an unscheduled asthma-
related visit to a health care provider. Asthma symptom
scores were recorded twice daily for the duration of the
study. Symptoms were assessed on a scale of 0 (no
symptoms) to 4 (marked discomfort). Rescue SABA use
(puffs/day) was recorded daily by subjects for the dura-
tion of the study. Subjects completed the Asthma Qual-
ity of Life Questionnaire (AQLQ) [28] at baseline and
after dosing.
Additional evaluations
Skin prick testing of common food and aeroallergens
was performed during screening for both studies and on
study day 28 for study 1 [29]. In both studies, spirome-
try was performed according to existing guidelines [30].
Statistical analyses
Formal sample size calculations were not applicable for
assessment of the primary objective (safety/tolerability
profile). No statistical hypothesis testing was performed
for this end point. Data analyses were conducted using
the SAS System (SAS Institute Inc., Cary, NC).
AEs and SAEs were described using the MedDRA
Adverse Event Thesaurus by system organ class, sever-
ity, and relationship to study drug through 18 weeks
after the last dose (day 150). Laboratory values with a
higher toxicity grade than that observed at baseline were
recorded as AEs. The day 0 value before study drug
administration was used as a baseline for laboratory
parameters. Study discontinuation blood samples were
summarized at the closest nominal time point that did
not already have a value.
The original design for study 2 included 3 cohorts
( 5 0m g ,1 0 0m g ,a n d2 0 0m gMEDI-528), each with 18
subjects randomized 2:1 to receive MEDI-528 or placebo.
Sample size calculations were based on two-sample t test
of the reduction in the maximum decline of FEV1 after
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cally significant difference in the maximum decline in
FEV1 was greater than 80% based on an assumption of a
20% fall in the placebo group and 65% reduction in the
maximum decline of FEV1 in the combined group (36
subjects) on active treatment versus placebo (18
subjects).
Serum concentrations and PK parameters were ana-
lyzed using WinNonlin (Pharsight, St. Louis, MO) and
descriptive statistics summarized for each MEDI-528
treatment group. The number of subjects exhibiting
anti-MEDI-528 antibodies was summarized, and
all valid assay results from subjects who received
any study drug were included in immunogenicity
summaries.
No formal statistical hypothesis tests were conducted
for exploratory variables (pulmonary function, asthma
exacerbations, symptom scores, rescue SABA use, qual-
ity of life). These variables were examined for their
medical/clinical implications.
Two-sample t tests were used to explore the change
from baseline in FEV1 and asthma symptom score
between MEDI-528 and placebo groups. The Fisher
exact test was used to explore the difference in asthma
exacerbation proportions between the placebo and
MEDI-528 groups. The total number of exacerbations
per subject during the study was noted.
Results
Demographics and baseline characteristics
In study 1, 36 subjects were randomized between June
2007 and February 2008 at 8 sites, and 33 completed the
study through day 150. Two MEDI-528-treated subjects
were lost to follow-up and 1 placebo-treated subject
withdrew due to an asthma exacerbation requiring hospi-
talization. All 36 subjects were evaluable (ie, received
≥7 doses of study drug) and included in the safety ana-
lyses (Figure 1A). There were more ex-smokers in the
placebo group, otherwise the groups’ baseline character-
istics were comparable (Table 1).
Enrolled
(N=36)
Enrolled
(N=11)
Discontinued
due to SAE
(n=1)
Lost to 
follow-up
(n=1)
Lost to 
follow-up
(n=1)
Completed
(n=8)
Completed
(n=8)
Completed
(n=8)
Completed
(n=9)
MEDI-528 1.0 mg/kg
(n=9)
MEDI-528 0.3 mg/kg
(n=9)
Placebo
(n=9)
Placebo
(n=4)
MEDI-528 50 mg
(n=7)
MEDI-528 3.0 mg/kg
(n=9)
Lost to 
follow-up
(n=1)
Completed (n = 3)
Evaluable (n = 2)
Withdrew
consent
(n=1)
Completed (n = 6)
Evaluable (n = 7)
(B)
(A)
Figure 1 Flow diagram for subjects in studies 1 (A) and 2 (B).
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with 50 mg of MEDI-528 or placebo between February
a n dM a y2 0 0 8a t4s i t e s ,a n d9c o m p l e t e dt h es t u d y
through day 150 (Figure 1B). Nine subjects were evalu-
able (ie, received ≥4 doses of study drug). Two placebo-
treated subjects were not evaluable (1 received only 2
doses of study drug and 1 was lost to follow-up). All 11
subjects were included in the safety analyses. Baseline
characteristics were similar between study groups
(Table 1).
Safety profile
T h em o s tf r e q u e n t l yr e p o r t e dA E si ns t u d y1a r el i s t e d
in Table 2. Severe AEs were reported in 4 placebo-trea-
ted subjects (vomiting, n = 1; elevated lipase, n = 2;
asthma, n = 1) and 2 subjects receiving MEDI-528 0.3
mg/kg (severe diarrhea, n = 1; elevated alanine amino-
tranferase [ALT], n = 1). The severe asthma AE in the 1
placebo-treated subject was an SAE (asthma exacerba-
tion requiring hospitalization); this subject was discon-
tinued from the study. The elevated ALT seen in the
MEDI-528-treated subject was noted on the first day of
dosing. This subject received no further drug and the
elevated levels resolved by study day 42. No deaths were
noted during this study.
Abnormal but clinically nonsignificant ECG results were
detected during the study in 5 placebo-treated subjects, 5
subjects in the MEDI-528 0.3-mg/kg group, and 2 subjects
each in the MEDI-528 1-mg/kg and 3-mg/kg groups. One
subject in the MEDI-528 3-mg/kg group exhibited an
asymptomatic elevation of troponin levels at a single time
point on study day 84. No significant changes in the
central nervous system were observed from the brain MRI
or focused neurological examinations.
The most frequently reported AEs in study 2 are
listed in Table 3. A total of 5 severe AEs occurred in 4
subjects; 3 placebo-treated subjects had 1 event each
(eye infection, cough, drug hypersensitivity) and 1
MEDI-528-treated subject had 2 events (sunburn, back
pain). No significant ECG changes occurred and no ele-
vations in troponin levels were observed. One SAE
occurred in a MEDI-528-treated subject (abnormal
brain MRI results). The subject had a 6- × 4-mm left-
sided pontine hyperintensity noted on the day 28 MRI
that was not present at baseline. The investigator con-
sidered the event possibly related to study drug, result-
ing in a clinical hold of the study. A repeat MRI with
gadolinium contrast showed no abnormal findings or
pontine hyperintensity. Review by an independent neu-
roradiologist determined the initial MRI finding to be
an artifact. The clinical hold was lifted, but the study
was discontinued due to the length of the delay.
Pharmacokinetics and immunogenicity
In study 1, limited PK parameters were estimable
because the dosing interval for MEDI-528 was not con-
stant, alternating between 3 days and 4 days, and PK
sampling was sparse.
After the last MEDI-528 dose, maximum serum concen-
trations were generally achieved between 3 and 4 days
across dose levels (Table 4). Mean maximum concentration
after the last dose of 0.3 mg/kg to 3 mg/kg, respectively,
Table 1 Demographics and Baseline Characteristics (ITT Population)
Study 1 Study 2
MEDI-528
Parameter Placebo
(n = 9)
0.3 mg/kg
(n = 9)
1 mg/kg
(n = 9)
3 mg/kg
(n = 9)
Placebo
(n = 4)
MEDI-528
50 mg (n = 7)
Mean age, years (range) 38.6 (22-63) 38.2 (18-61) 33.2 (19-57) 28.9 (19-55) 31.8 (19-47) 32.1 (19-39)
Female, n (%) 8 (88.9) 8 (88.9) 5 (55.6) 5 (55.6) 2 (50) 6 (85.7)
Race/Ethnicity, n (%)
White/non-Hispanic 8 (88.9) 6 (66.7) 9 (100) 5 (55.6) 3 (75.0) 6 (85.7)
White/Hispanic 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3)
Black 0 (0.0) 2 (22.2) 0 (0.0) 3 (33.3) 1 (25.0) 0 (0.0)
Asian 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0)
Multiracial 1 (11.1) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mean weight, kg (range) 68.5 (52.0-93.9) 78.9 (58.2-99.7) 72.3 (43.0-99.1) 72.7 (57.6-97.7) 77.3 (57.7-93.2) 73.4 (52.7-97.3)
Mean (SD) FEV1 (L)* 2.8 (0.58) 2.8 (0.93) 3.2 (0.73) 3.4 (0.43) 3.3 (1.25) 2.8 (0.56)
Ever smoked, n (%) 7 (77.8) 1 (11.1) 1 (11.1) 0 (0.0) 1 (25.0) 2 (28.6)
Exacerbations in past year, no. (%)
None 4 (44.4) 6 (66.7) 6 (66.7) 4 (44.4) 2 (50.0) 3 (42.9)
1-2 5 (55.6) 3 (33.3) 2 (22.2) 5 (55.6) 2 (50.0) 4 (57.1)
3-5 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0)
*Measurements from evaluable subjects (those who received ≥7o r≥4 doses of the study drug in study 1 and study 2, respectively); ITT = intent to treat (all
randomized subjects); SD = standard deviation; FEV1 = forced expiratory volume in 1 second.
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from 13.7 μg/mL to 105.5 μg/mL; similar dose proportion-
ality was noted for trough concentrations, which increased
from 11.7 μg/mL to 90.4 μg/mL. Mean half-life was similar
across dose levels (range, 35-38 days).
Comparison of trough concentrations after the first and
last doses yielded accumulation index values between 5
and 10 across dose levels. The fluctuation of MEDI-528
concentrations within a dosing interval was small, consis-
tent with the frequency of dosing and half-life (Figure 2).
No anti-MEDI-528 antibodies, defined as antibody
titer of >10, were detected in any group during study 1
or study 2.
Pulmonary function
Pulmonary function was generally unchanged throughout
both studies. FEV1 values were comparable among groups
at baseline and at the end of the studies (Table 5). In study
1, FEV1 percent predicted values were comparable at base-
line and end of study (Table 5).
Asthma control and quality of life
Asthma control and quality of life results are shown in
Table 5. In both studies, a trend toward improvement in
the overall mean asthma symptom scores was noted dur-
ing the treatment period in all subjects compared with
baseline values. Overall mean rescue SABA use during
both studies was comparable among groups, and overall
mean AQLQ scores were comparable between the MEDI-
528 groups and placebo at baseline and during the study.
In study 1, fewer subjects having ≥1 asthma exacerba-
tion were observed in the combined MEDI-528 group
(n = 1 of 27) compared with the placebo group (n = 2
of 9; P = 0.148). The one MEDI-528-treated subject was
receiving the lowest dose. The 2 placebo-treated subjects
had a total of 4 asthma exacerbation episodes (1 subject
had 1 episode; 1 subject had 3 episodes).
In study 2, no asthma exacerbations were reported.
Exercise challenge test
In study 2, multiple doses of MEDI-528 resulted in a
reduction in the mean maximum percentage decrease in
FEV1 after exercise as compared to placebo (Table 6). The
Table 2 Most Frequently Reported Adverse Events in
Study 1 (Safety Population*)
No. (%) of Subjects
Event MEDI-528
Placebo
(n = 9)
0.3
mg/kg
(n = 9)
1 mg/
kg
(n = 9)
3 mg/
kg
(n = 9)
Total
(n = 27)
Blood glucose
increase
3 (33.3) 5 (55.6) 2 (22.2) 1 (11.1) 8 (29.6)
Nasopharyngitis 4 (44.4) 3 (33.3) 1 (11.1) 2 (22.2) 6 (22.2)
Blood bicarbonate
decrease
1 (11.1) 1 (11.1) 2 (22.2) 3 (33.3) 6 (22.2)
Injection site pain 0 (0.0) 3 (33.3) 0 (0.0) 3 (33.3) 6 (22.2)
Pharyngolaryngeal
pain
1 (11.1) 2 (22.2) 3 (33.3) 0 (0.0) 5 (18.5)
Lymphocyte count
decrease
0 (0.0) 0 (0.0) 4 (44.4) 1 (11.1) 5 (18.5)
Injection site
bruising
1 (11.1) 0 (0.0) 1 (11.1) 3 (33.3) 4 (14.8)
Presence of protein
in urine
1 (11.1) 2 (22.2) 1 (11.1) 1 (11.1) 4 (14.8)
Vomiting 3 (33.3) 0 (0.0) 1 (11.1) 1 (11.1) 2 (7.4)
Urinary tract
infection
2 (22. 2) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.4)
Presence of blood in
urine
1 (11.1) 1 (11.1) 1 (11.1) 0 (0.0) 2 (7.4)
Blood chloride
increase
2 (22.2) 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.7)
Blood potassium
decrease
2 (22.2) 0 (0.0) 1 (11.1) 0 (0.0) 1 (3.7)
Influenza 2 (22.2) 0 (0.0) 1 (11.1) 0 (0.0) 1 (3.7)
Lipase increase 2 (22.2) 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.7)
Sinusitis 2 (22.2) 0 (0.0) 1 (11.1) 0 (0.0) 1 (3.7)
Values are shown in descending order of frequency in the total MEDI-528
group.
*Consisted of all subjects who received the study drug.
Table 3 Most Frequently Reported Adverse Events in
Study 2 (Safety Population*)
No. (%) of Subjects
Event Placebo
(n = 4)
MEDI-528 50 mg
(n = 7)
Blood glucose increased 0 (0.0) 2 (28.6)
Back pain 1 (25.0) 1 (14.3)
Injection site irritation 1 (25.0) 1 (14.3)
Blood bicarbonate increased 0 (0.0) 1 (14.3)
Cyst 0 (0.0) 1 (14.3)
Lipase increased 0 (0.0) 1 (14.3)
Lower respiratory tract infection 0 (0.0) 1 (14.3)
Nuclear MRI abnormal 0 (0.0) 1 (14.3)
Values are shown in descending order of frequency in the MEDI-528 group.
MRI = magnetic resonance imaging.
*Consisted of all subjects who received the study drug.
Table 4 MEDI-528 Multiple-Dose Pharmacokinetic
Parameters in Study 1
Cohort Cmax
(μg/mL)
Tmax
(day)
T1/2
(day)
Accumulation
index*
0.3 mg/kg
(n = 9)
13.7 ± 2.7
† 3.5 ±
2.1
†
37.1 ± 7.5
† 5.2 ± 2.0
‡
1 mg/kg
(n = 9)
52.1 ± 33.0 3.7 ± 2.3 35.0 ±
11.5
9.9 ± 4.5
3 mg/kg
(n = 9)
105.5 ±
31.0
3.9 ± 2.6 37.7 ± 7.5 6.7 ± 1.8
Values are mean ± SD. Cmax = maximum concentration; Tmax = time to
maximum concentration; T1/2 = half-life.
*Accumulation index was based on trough concentration after first and last
dose.
†n=8 .
‡n=7 .
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Figure 2 MEDI-528 mean serum concentrations in study 1. Mean maximum concentration after the last dose of 0.3 mg/kg to 3 mg/kg,
respectively, mean half-life, trough concentrations after the first and last doses were measured. Mean concentrations of MEDI-528 increased in a
dose-proportional manner and peaked after the last dose of the study drug.
Table 5 Exploratory Analyses in Studies 1 and 2 (Evaluable Population)
Study 1 Study 2
MEDI-528
Parameter Placebo 0.3 mg/kg 1 mg/kg 3 mg/kg Placebo MEDI-528 50
mg
Pulmonary function
FEV1,L
Baseline 2.8 ± 0.58
(n = 9)
2.8 ± 0.93
(n = 9)
3.2 ± 0.73
(n = 9)
3.4 ± 0.43
(n = 9)
3.3 ± 1.25
(n = 2)
2.8 ± 0.56
(n = 7)
End of study 2.9 ± 0.48
(n = 8)
2.6 ± 1.02
(n = 9)
3.3 ± 0.67
(n = 8)
3.6 ± 0.56
(n = 8)
3.0 ± 1.30
(n = 2)
2.9 ± 0.42
(n = 5)
FEV1, % predicted
Baseline 89.3 ± 10.49
(n = 9)
85.8 ± 7.95
(n = 9)
86.0 ± 12.07
(n = 9)
93.3 ± 12.40
(n = 9)
End of study 91.4 ± 8.87
(n = 8)
79.2 ±
11.04
(n = 9)
90.3 ± 9.64
(n = 8)
99.6 ± 13.14
(n = 8)
Asthma symptom score, overall
Baseline 1.11 ± 0.83
(n = 6)
1.87 ± 1.70
(n = 7)
1.37 ± 1.59
(n = 6)
0.00 ± N/A
(n = 1)
1.92 ± 1.53
(n = 2)
0.93 ± 0.82
(n = 6)
Treatment 0.74 ± 0.55
(n = 7)
0.91 ± 0.63
(n = 6)
1.10 ± 1.49
(n = 6)
0.13 ± 0.18
(n = 2)
0.91 ± 0.07
(n = 2)
0.41 ± 0.66
(n = 6)
Rescue short-acting b2-agonist use (no. of puffs/day), overall
during study
0.63 ± 0.60
(n = 9)
0.65 ± 0.51
(n = 8)
0.66 ± 0.80
(n = 8)
0.02 ± 0.04
(n = 5)
0.22 ± 0.02
(n = 2)
0.28 ± 0.32
(n = 7)
AQLQ score, overall
Baseline 5.56 ± 1.11
(n = 9)
5.20 ± 0.79
(n = 9)
5.73 ± 0.70
(n = 9)
5.97 ± 0.78
(n = 9)
5.73 ± 0.11
(n = 2)
5.75 ± 0.65
(n = 7)
Day 28 5.64 ± 0.82
(n = 9)
5.68 ± 0.66
(n = 9)
5.95 ± 0.87
(n = 9)
6.07 ± 0.60
(n = 9)
6.22 ± 0.09
(n = 2)
5.94 ± 0.57
(n = 7)
Values are mean ± SD.
AQLQ = Asthma Quality of Life Questionnaire; FEV1 = forced expiratory volume in 1 second.
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Page 7 of 10mean absolute maximum decline in FEV1 at study day 56
was -0.04 L for the MEDI-528 group compared with -0.60
L for the placebo group (P < 0.01). Differences at all other
data points did not achieve statistical significance (data
not shown). Time to return to 90% of baseline FEV1 fol-
lowing exercise challenge was shorter during the screening
period prior to dosing with study drug and at all subse-
quent study days for the MEDI-528 group as compared
with placebo. Furthermore, the time to return to 90% of
baseline FEV1 improved in the MEDI-528 group at study
days 28 and 56, while there was no improvement in the
placebo group. A post hoc analysis showed that 6 of 7
MEDI-528-treated subjects were responders at study day
28, 7 of 7 at day 56, and 6 of 6 at day 150. There were no
placebo-treated responders at days 28 and 56, and there
was 1 responder at day 150 (Figure 3).
Discussion
In both studies, subjects tolerated multiple SC doses of
MEDI-528, with AE, severe AE and SAE rates similar to
placebo-treated subjects. No subjects developed anti-
MEDI-528 antibodies. MEDI-528 exhibited linear PK,
with peak and trough concentrations increasing in an
approximately dose-proportional manner over the dose
range studied. The half-life values (35-38 days) were
consistent with those observed in the high-dose groups
of the single-dose SC study of healthy volunteers [24],
namely, the 3-mg/kg (half-life, 44 days) and 9-mg/kg
(half-life, 33 days) doses. In addition, these results are in
accord with findings from the 2 studies conducted in
healthy volunteers [24]. In those studies, MEDI-528 had
an acceptable safety profile, with no SAEs or deaths
reported.
Throughout study 1, pulmonary function was essen-
tially unchanged and SABA use was comparable among
groups. Overall, asthma symptom scores showed a trend
toward improvement in all subjects. A trend toward
fewer subjects having ≥1 asthma exacerbation was
observed in MEDI-528-treated subjects in study 1 com-
pared with placebo-treated subjects. This finding is of
unclear significance as blocking IL-9 may result in a
reduction in AHR [13,14] and AHR has not been clearly
related to asthma exacerbations.
Although the actions of IL-9 are not fully understood,
IL-9 is believed to play an important role in the traffick-
ing and function of mast cells [15,16]. Local IL-9 produc-
tion from inflammatory cells would theoretically result in
the recruitment and differentiation of mast cell progeni-
tors from the bone marrow to the lung. Blocking IL-9
would therefore not be expected to have an immediate
clinical effect, but this would rather be dependent on the
loss of resident mast cells in the tissue.
The results of study 2 are intriguing in that they sug-
gest that blocking IL-9 with MEDI-528 may have an
effect on EIB, which is dependent on mast cell degra-
nulation [19]. The maximum effect of MEDI-528 was
seen at study day 56, which would be consistent with a
later onset of action. Future studies should consider
that a period of chronic dosing may be required before
seeing maximum clinical effect. Conclusions from
study 2 are unfortunately limited in that it was prema-
turely halted.
Because of the small sample size in both studies, firm
conclusions regarding the clinical activity of MEDI-528
cannot be drawn from these results. The potential bene-
fits of MEDI-528 observed in both studies should be
interpreted with caution as these studies were also lim-
ited by the mild disease severity of the study population.
Conclusions
In conclusion, prior and current results suggest that
MEDI-528 has acceptable safety and tolerability profiles
and provide evidence of clinical activity in mild to mod-
erate asthmatics. Further studies are warranted to assess
Table 6 Mean (SD) maximum percentage change in FEV1 after exercise in study 2
Baseline P Value Day 28 P Value Day 56 P Value Day 150 P Value
MEDI-528 (n = 7)* -22.20 (4.38) 0.62 -6.49 (11.73) 0.22 -1.40 (2.27) 0.17 -5.04 (3.91) 0.52
Placebo (n = 2) -20.20 (4.16) -12.60 (1.53) -20.10 (7.41) -15.20 (15.48)
*For day 150, n = 6. P values are based on two-sample t test between placebo and MEDI-528 groups.
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Figure 3 Mean maximum percentage decline in FEV1 after
exercise for each individual subject in study 2. Multiple doses of
MEDI-528 resulted in a reduction in the mean maximum percentage
decrease in FEV1 after exercise as compared to placebo.
Parker et al. BMC Pulmonary Medicine 2011, 11:14
http://www.biomedcentral.com/1471-2466/11/14
Page 8 of 10the clinical efficacy of MEDI-528 for treating patients
with inadequately controlled asthma.
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